AD 01
CAS No. 959961-23-0
AD 01( —— )
Catalog No. M30749 CAS No. 959961-23-0
FKBPL (FK506-binding protein like)-based peptide. Binds to and upregulates expression of CD44. Inhibits breast cancer stem cell (BCSC) growth. Decreases pluripotency markers and promotes differentiation of BCSCs. Also inhibits endothelial cell migration as well as tubule and microvessel formation in vitro and in vivo. Blocks tumor growth in xenograft models.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAD 01
-
NoteResearch use only, not for human use.
-
Brief DescriptionFKBPL (FK506-binding protein like)-based peptide. Binds to and upregulates expression of CD44. Inhibits breast cancer stem cell (BCSC) growth. Decreases pluripotency markers and promotes differentiation of BCSCs. Also inhibits endothelial cell migration as well as tubule and microvessel formation in vitro and in vivo. Blocks tumor growth in xenograft models.
-
DescriptionFKBPL (FK506-binding protein like)-based peptide. Binds to and upregulates expression of CD44. Inhibits breast cancer stem cell (BCSC) growth. Decreases pluripotency markers and promotes differentiation of BCSCs. Also inhibits endothelial cell migration as well as tubule and microvessel formation in vitro and in vivo. Blocks tumor growth in xenograft models.
-
In Vitro——
-
In VivoAD 01 (≥0.003 mg/kg/day, ip) exhibits significant anti-tumor activity in DU145 tumors. Animal Model:Balb-c severe compromised immuno-deficient (SCID) mice.Dosage:0.3 mg/kg/day. Administration:I,P., for 14 days.Result:Significantly lowered the tumor size.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number959961-23-0
-
Formula Weight2703.94
-
Molecular FormulaC115H187N33O42
-
Purity>98% (HPLC)
-
Solubilitywater:1 mg/mL
-
SMILES[H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yakkundi et al (2013) The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway. PLoS One. 8 e55075 PMID:
molnova catalog
related products
-
Liriope muscari bail...
Liriope muscari baily saponins C has an anti-thrombotic activity due to down-regulation of the increased mRNA expression levels of TF and IL-6.
-
Ladiratuzumab
LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.
-
YX-2-107
YX-2-107 is a selective and potent CDK6-degrading PROTAC with an IC50 value of 4.4 nM.YX-2-107 inhibits RB phosphorylation and FOXM1 expression in vitro, and inhibits the development of Ph+ ALL in rats.
Cart
sales@molnova.com